Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus
Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus: A Randomized Clinical Trial
All India Institute of Medical Sciences, Bhubaneswar
60 participants
Oct 10, 2025
INTERVENTIONAL
Conditions
Summary
Many of the patients with oral lichen planus (OLP) either fail to achieve complete remission or experience frequent relapses with conventional topical corticosteroid therapy, which is currently the mainstay of treatment. Long-term corticosteroid use is limited by local and systemic adverse effects, and many patients develop steroid resistance or intolerance. To overcome these limitations, combination therapy with agents having complementary mechanisms may improve therapeutic outcomes, reduce steroid requirements, and minimize associated adverse effects. Tofacitinib, a Janus kinase (JAK1/JAK3) inhibitor, modulates the JAK-STAT signaling pathway, thereby reducing inflammatory cytokine production involved in OLP pathogenesis. Preliminary case series and pilot trials have shown promising results with tofacitinib in OLP. However, to date, no randomized controlled trial has evaluated the efficacy and safety of add-on oral tofacitinib with standard topical steroid therapy in OLP. Hence, investigators considered tofacitinib to be a candidate drug for add-on therapy due to its anti-inflammatory and immunomodulatory properties. Adding tofacitinib to ongoing topical triamcinolone therapy may increase the response rate, reduce adverse drug reactions by lowering steroid dose requirements, or achieve a quicker therapeutic effect. Therefore, the present randomized controlled trial has been planned to evaluate the efficacy and safety of oral tofacitinib as an add-on therapy in patients with OLP.
Eligibility
Inclusion Criteria3
- Patients aged ≥18 of either sex with the clinical diagnosis of oral lichen planus.
- Patients with a PGA score of ≥3 (moderate and severe oral LP).
- Patients who are willing to give informed written consent.
Exclusion Criteria11
- Treatment with a systemic corticosteroid within the last 4 weeks.
- Patients on immunosuppressive agents such as azathioprine, cyclosporine, and others within one month of recruitment.
- Patients with a clinical history and any lesion distribution suspicious of a lichenoid drug eruption, and patients with other skin diseases.
- Past or current history of any malignancy, including moderate to severe dysplasia of the oral mucosa on oral biopsy.
- Severe active infection, including active tuberculosis, hepatitis B, or C infection
- Patients with cytopenia (Hb <9g/dl, leukocyte count <4000/mm3, platelet count <100,000/mm3)
- The patient with a history of alcohol abuse.
- Decreased liver or renal function (creatinine > 2.0mg/dl, total bilirubin > 2.5 mg/dl).
- Severe acute infection, uncontrolled diabetes mellitus, congenital or acquired immunodeficiency, severe cardiac disease (NYHA grade IV), MI in the last four weeks, severe schizophrenia, or depression.
- Patient with a history of hypersensitivity to topical Triamcinolone or Tofacitinib.
- Pregnancy and lactation, women of childbearing age without effective contraception.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients in the test group will get tofacitinib 5mg capsules twice daily as an add on to triamcinolone ointment
Patients in the control group will receive identical looking capsules as placebo with triamcinolone ointment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07131813